JP2025508495A - インターフェロン関連疾患の治療におけるｈｐｋ１阻害剤の応用 - Google Patents

インターフェロン関連疾患の治療におけるｈｐｋ１阻害剤の応用 Download PDF

Info

Publication number
JP2025508495A
JP2025508495A JP2024550879A JP2024550879A JP2025508495A JP 2025508495 A JP2025508495 A JP 2025508495A JP 2024550879 A JP2024550879 A JP 2024550879A JP 2024550879 A JP2024550879 A JP 2024550879A JP 2025508495 A JP2025508495 A JP 2025508495A
Authority
JP
Japan
Prior art keywords
group
substituted
unsubstituted
virus
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024550879A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025508495A5 (enExample
Inventor
ウェイ，ウェンジュエン
ホァン，タオ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asclepieion Pharmaceutical Co Ltd
Original Assignee
Asclepieion Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asclepieion Pharmaceutical Co Ltd filed Critical Asclepieion Pharmaceutical Co Ltd
Publication of JP2025508495A publication Critical patent/JP2025508495A/ja
Publication of JP2025508495A5 publication Critical patent/JP2025508495A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024550879A 2022-02-23 2023-02-23 インターフェロン関連疾患の治療におけるｈｐｋ１阻害剤の応用 Pending JP2025508495A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202210168693.X 2022-02-23
CN202210168693.XA CN116672450A (zh) 2022-02-23 2022-02-23 Hpk1抑制剂在治疗干扰素相关疾病中的应用
PCT/IB2023/051675 WO2023161844A1 (zh) 2022-02-23 2023-02-23 Hpk1抑制剂在治疗干扰素相关疾病中的应用

Publications (2)

Publication Number Publication Date
JP2025508495A true JP2025508495A (ja) 2025-03-26
JP2025508495A5 JP2025508495A5 (enExample) 2026-03-02

Family

ID=87764942

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024550879A Pending JP2025508495A (ja) 2022-02-23 2023-02-23 インターフェロン関連疾患の治療におけるｈｐｋ１阻害剤の応用

Country Status (8)

Country Link
US (1) US20250161319A1 (enExample)
EP (1) EP4483880A4 (enExample)
JP (1) JP2025508495A (enExample)
KR (1) KR20240163080A (enExample)
CN (1) CN116672450A (enExample)
AU (1) AU2023226510A1 (enExample)
CA (1) CA3244921A1 (enExample)
WO (1) WO2023161844A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116514728A (zh) * 2022-01-28 2023-08-01 赛诺哈勃药业（成都）有限公司 一种喹唑啉衍生物及其用途
WO2025228828A1 (en) * 2024-04-29 2025-11-06 Merck Patent Gmbh Carboxamide compounds for the treatment and prevention of viral diseases

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR060358A1 (es) * 2006-04-06 2008-06-11 Novartis Vaccines & Diagnostic Quinazolinas para la inhibicion de pdk 1
WO2015083833A1 (ja) * 2013-12-06 2015-06-11 カルナバイオサイエンス株式会社 新規キナゾリン誘導体
EP3601259B1 (en) * 2017-03-30 2022-02-23 F. Hoffmann-La Roche AG Isoquinolines as inhibitors of hpk1
TW202019905A (zh) * 2018-07-24 2020-06-01 瑞士商赫孚孟拉羅股份公司 異喹啉化合物及其用途
WO2020255022A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and aminopyridine derivatives as hpk1 inhibitors
TW202116753A (zh) * 2019-07-11 2021-05-01 大陸商南京征祥醫藥有限公司 以噌啉作為hpk1的抑制劑
KR20210143131A (ko) * 2020-05-19 2021-11-26 한국화학연구원 2-아미노퀴나졸린 유도체 및 이를 포함하는 항바이러스용 조성물
CN113797202B (zh) * 2020-06-16 2024-06-28 珠海宇繁生物科技有限责任公司 Hpk1激酶抑制剂在预防和/或治疗动物的病原体感染中的应用
CN114315798B (zh) * 2020-09-29 2025-03-25 安思科(苏州)医药科技有限公司 喹唑啉类化合物及其药物组合物

Also Published As

Publication number Publication date
CN116672450A (zh) 2023-09-01
WO2023161844A1 (zh) 2023-08-31
CA3244921A1 (en) 2025-06-13
EP4483880A1 (en) 2025-01-01
EP4483880A4 (en) 2026-03-11
AU2023226510A1 (en) 2024-10-10
KR20240163080A (ko) 2024-11-18
US20250161319A1 (en) 2025-05-22

Similar Documents

Publication Publication Date Title
CN113286794B (zh) Kras突变蛋白抑制剂
TWI659957B (zh) 新穎吡唑并［3,4-d］嘧啶化合物或其鹽
CN114163457A (zh) 嘧啶并五元氮杂环化合物及其用途
CN104066735B (zh) 作为akt激酶抑制剂的取代的咪唑并吡嗪
JP2025508495A (ja) インターフェロン関連疾患の治療におけるｈｐｋ１阻害剤の応用
EP3858833B1 (en) Aminonorbornane derivative and manufacture method thereof and use thereof
CN107151250B (zh) 嘧啶类七元环化合物、其制备方法、药用组合物及其应用
CN115057855A (zh) 取代五元并六元杂环类化合物、其制备方法、药物组合及其用途
KR20250005363A (ko) 인간 병원체 감염의 예방 및/또는 치료에서 hpk1 억제제의 용도
EP4497752A1 (en) Pyrimido-pyridazinone compound as toll-like receptor agonist
JP2023145644A (ja) ジヒドロイソキノリン系化合物
WO2018149231A1 (zh) 7H-吡咯并[2,3-d]嘧啶衍生物及抗肿瘤的应用
WO2022171118A1 (zh) 一种具有抗肿瘤活性的化合物及其用途
CN121889397A (zh) 化合物或其盐及其制造方法、包含化合物或其盐的药物组合物及其制造方法
WO2020143798A1 (zh) 内环硫脒酰胺-芳基酰胺类化合物及其治疗乙型肝炎的用途
CN118126086A (zh) 一类磷酸酯类化合物、其制备方法及应用
CN117402185A (zh) 三嗪类化合物及其在药物中的应用
KR20180020119A (ko) 새로운 5형포스포디에스테라아제 억제제 및 그 용도
CN111303163A (zh) 具有jak激酶抑制活性化合物、制备方法、组合物及用途
CN115381824B (zh) 周期蛋白依赖性激酶9抑制剂的用途
RU2839716C1 (ru) Производные аденозина - ингибиторы репродукции вирусов, относящихся к роду Flavivirus
CN115381823B (zh) 一种周期蛋白依赖性激酶9抑制剂的用途
CN110857298B (zh) 杂芳基并四氢吡啶类化合物、包含其的药物组合物、其制备方法及其用途
HK40104934A (zh) 新型肝选择性聚腺苷酸化聚合酶抑制剂及其使用方法
TW202214592A (zh) 取代喹唑啉類化合物、其製備方法、藥物組合及應用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260219

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260219